Home / Health / CAR-T Therapy Offers New Hope for Stiff Person Syndrome
CAR-T Therapy Offers New Hope for Stiff Person Syndrome
9 Nov
Summary
- Novel immunotherapy, CAR-T cell therapy, shows promising results for Stiff Person Syndrome.
- Patients treated with CAR-T therapy have returned to work and hobbies.
- The treatment reprograms a patient's own immune cells to fight the autoimmune disease.
Neurologists at the Mayo Clinic have reported significant progress in treating Stiff Person Syndrome (SPS), a debilitating autoimmune condition affecting the central nervous system. A novel form of immunotherapy, known as CAR-T cell therapy, has yielded "exciting" and "very encouraging" results in a trial.
This groundbreaking treatment reprograms a patient's own T cells to target and eliminate disease-causing cells. Remarkably, patients who previously required assistance for daily tasks and mobility have experienced dramatic improvements. Some individuals have successfully returned to their jobs and resumed cherished hobbies, marking a significant departure from the limited functional recovery typically seen with current therapies.
Patients like Jonathan Walden have shared transformative experiences, reporting a complete return to their pre-illness activities, including work, hunting, and fishing, with no episodes since treatment. Shari St Germain also described regaining the ability to walk on a treadmill for seven minutes, a milestone that brought her to tears. This therapy offers tremendous hope for those living with SPS and may hold potential for other immune-mediated neurological conditions.
